Akamai Technologies (AKAM) Margin Compression Challenges Bullish Earnings Growth Narrative

Advertisement

Akamai Technologies (AKAM) FY 2025 earnings snapshot

Akamai Technologies (AKAM) has wrapped up FY 2025 with fourth quarter revenue of US$1,094.9 million and basic EPS of US$0.59, set against trailing twelve month revenue of US$4.2 billion and EPS of US$3.11 that frame the latest print within a fuller year view. Over recent periods the company has seen quarterly revenue move from US$1,019.9 million and EPS of US$0.93 in Q4 2024 through US$1,015.1 million and EPS of US$0.83 in Q1 2025 to US$1,054.6 million and EPS of US$0.98 in Q3 2025, giving investors a clear run-rate context for assessing FY 2025. With a current net margin of 10.7% versus 12.7% a year earlier, investors may now focus on how to weigh slightly thinner profitability against the earnings growth potential highlighted in recent forecasts.

See our full analysis for Akamai Technologies.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the widely followed narratives around Akamai's growth potential, risk profile, and margin trajectory.

See what the community is saying about Akamai Technologies

NasdaqGS:AKAM Revenue & Expenses Breakdown as at May 2026
NasdaqGS:AKAM Revenue & Expenses Breakdown as at May 2026

Margins under pressure as net income cycles lower

  • Net income excluding extra items was US$85.1 million in Q4 2025, down from US$140.2 million in Q3 2025 and US$139.9 million in Q4 2024, while trailing net margin sits at 10.7% compared with 12.7% a year earlier.
  • Bears argue that intensifying price competition and higher infrastructure costs could keep squeezing profitability, and the recent step down in quarterly net income gives that concern some support, yet:
    • Trailing twelve month net income is US$452.0 million, which still reflects a sizeable profit base even after the margin compression noted in the risk summary.
    • Consensus expectations in the data point to earnings growth of about 16.2% per year, which challenges the most pessimistic view that margins are locked into a weaker long term level.
Skeptics warn that recent margin pressure could be the start of a longer squeeze on profits, while others point to the earnings base and forecasts as evidence the story is more balanced. It is therefore worth lining this up with the detailed cautious case for Akamai đŸ» Akamai Technologies Bear Case.

6.4% revenue growth versus faster US market

  • Over the last year, revenue is reported as growing 6.4% annually compared with an 11.4% annual benchmark for the broader US market, while trailing twelve month revenue sits at about US$4.2b.
  • Consensus narrative suggests Akamai can still grow earnings even with slower top line expansion, and the data partly backs that up while also showing the trade off:
    • Earnings per share on a trailing basis is US$3.11, but the analysis notes earnings have declined 4.9% per year over the past five years, which tempers the headline that revenue is still rising.
    • Analysts in the consensus view expect earnings of US$751.8 million by around 2029, tying that outlook to forecasts for 7% annual revenue growth and margin improvement from 10.7% to 14.6% in the same period.

P/E premium and DCF fair value create mixed signals

  • The stock trades on a trailing P/E of 38x versus a US IT industry average of 20.6x and a peer average of 42.8x, while a DCF fair value of US$135.28 compares with the current share price of US$116.69 and an allowed analyst price target figure of US$114.24.
  • Bulls highlight that the current price sits about 13.7% below the DCF fair value in the supplied analysis, yet the premium P/E and below market revenue growth rate raise questions about how much optimism is already embedded:
    • Forecast earnings growth of around 16.2% per year is only slightly below the 16.4% US market forecast, which supports the idea that some growth premium could be justified at today’s multiple.
    • At the same time, five year earnings contraction of 4.9% per year and the 6.4% revenue growth rate versus the 11.4% US market benchmark show why some investors might be cautious about paying a P/E above the broader industry average.
Bulls argue that the combination of forecast earnings growth and a price below DCF fair value could set up a more attractive long term story if those forecasts play out. It can therefore be helpful to see how that optimistic case is built from the ground up 🐂 Akamai Technologies Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Akamai Technologies on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards in play, the picture is not one sided. It makes sense to review the data promptly and form your own judgement based on the 2 key rewards and 2 important warning signs.

See What Else Is Out There

Akamai is working with slower revenue growth than the wider US market, thinner margins, and a P/E that already sits above the broader industry average.

If you are concerned about paying up for this mix of slower growth and margin pressure, it is worth quickly scanning the 51 high quality undervalued stocks to spot stocks where expectations and price may be better aligned.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

‱ Connect an unlimited number of Portfolios and see your total in one currency
‱ Be alerted to new Warning Signs or Risks via email or mobile
‱ Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:AKAM

Akamai Technologies

Engages in the provision of security, delivery, and cloud computing solutions in the United States and internationally.

Mediocre balance sheet with very low risk.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
50 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7719.9% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9217.2% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$1907.4% undervalued
24 users have followed this narrative
0 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

CL
Clive_Thompson
6831 logo
Clive_Thompson on Green Tea Group ·

One of China's Fastest-Growing Restaurant Chains Trades on Just 7x Earnings and an 8% Dividend

Fair Value:HK$8.728.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AZ
PRG logo
aziz_22khi on PRG Holdings Berhad ·

WHERE DID THE SIX MILLION SHARES GO? THE PRG OWNERSHIP TRAIL INVESTORS CANNOT IGNORE

Fair Value:RM 0.4477.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BR
Brunhilde_Wagner
CPRT logo
Brunhilde_Wagner on Copart ·

Compounder to Cash Generator in Real Time

Fair Value:US$2710.3% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
85 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
193 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0
AN
CSMG3 logo
andre_k1tsg on Companhia de Saneamento de Minas Gerais ·

Gostei

0
|
0